Results 41 to 50 of about 453,541 (160)

Long-Term Survival of a Patient with Adenocarcinoma of the Esophagogastric Junction with a Portal Vein Tumor Thrombosis Who Underwent Palliative Total Gastrectomy: A Case Report

Case Reports in Oncology, 2017
Portal vein tumor thrombosis (PVTT) with advanced gastric cancer is very rare; when it occurs, it exhibits aggressive growth and carries a poor prognosis. In addition, definitive treatment has not been established due to insufficient data.
Sung Don Oh, Sung Jin Oh, Byoung Jo Suh, Jin Yong Shin, Jong Kwon Park   +4 more
doaj   +1 more source

Third Space Endoscopic Therapies for Benign Motility Disorders: A Narrative Review

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Objectives To review the evidence base, evolution, outcomes, adverse events (AEs), and management for third‐space endoscopy (TSE) procedures for management of benign motility disorders. Methods This review examines TSE procedures for motility disorders, reviewing the current available techniques, success, outcomes, and long‐term outcomes from ...
Sanjana Bhagwat, Amol Bapaye
wiley   +1 more source

Breast Metastasis from Esophagogastric Junction Cancer: A Case Report

Case Reports in Surgery, 2014
Metastasis to breast from nonmammary malignancy is only about 1.3–2.7%. A few cases of squamous cell carcinoma of esophagus and adenocarcinoma of stomach metastasizing to breast have been reported, but this is probably the first report of breast ...
Sanghamitra Jena, Samir Bhattacharya, Arnab Gupta, Shravasti Roy, Neetesh Kumar Sinha   +4 more
doaj   +1 more source

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

International Journal of Cancer, Volume 159, Issue 10, Page 2552-2561, 15 November 2026.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden, Tamara J. Huizer, Ben M. Eyck, Ate van der Gaast, Leni van Doorn, Marjolein Y. V. Homs, J. Jan B. van Lanschot, Joost J. M. E. Nuyttens, Lindsey Oudijk, Manon C. W. Spaander, Bas P. L. Wijnhoven, Bianca Mostert, Sjoerd M. Lagarde   +12 more
wiley   +1 more source

Short-Term and Long-Term Outcomes Following Transhiatal versus Right Thoracoabdominal Resection of Siewert Type II Adenocarcinoma of the Esophagogastric Junction

Cancer Management and Research, 2020
Jiadi Xing,* Maoxing Liu,* Kai Xu,* Pin Gao, Fei Tan, Zhendan Yao, Nan Zhang, Hong Yang, Chenghai Zhang, Ming Cui, Xiangqian Su Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery IV,
Xing J, Liu M, Xu K, Gao P, Tan F, Yao Z, Zhang N, Yang H, Zhang C, Cui M, Su X   +10 more
doaj  

MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti‐MET Antibody‐Drug Conjugate Therapy

International Journal of Cancer, Volume 159, Issue 10, Page 2606-2618, 15 November 2026.
ABSTRACT MET is an actionable receptor tyrosine kinase, and MET‐directed antibody–drug conjugates (ADCs) have recently entered clinical practice with FDA approval in non‐small cell lung cancer and are now being evaluated across gastrointestinal malignancies, with patient selection based on MET immunohistochemistry (IHC) 3+ membranous staining at ...
Tillmann Bedau, Thomas Zander, Hans Anton Schlößer, Hakan Alakus, Onur Mustafov, Reinhard Büttner, Christiane Bruns, Alexander Quaas   +7 more
wiley   +1 more source

Surgical principles for optimal treatment of esophagogastric junction adenocarcinoma

Annals of Gastroenterological Surgery, 2019
The incidence of esophagogastric junction (EGJ) adenocarcinoma is increasing worldwide. Management of these tumors remains controversial given their unique location between the esophagus and the stomach.
Tamar Nobel, Daniela Molena
doaj   +1 more source

Changing Pattern of Adenocarcinoma of the Esophagogastric Junction in Recent 10 Years: Experience at a Large Tertiary Medical Center in China

, 2012
Aims and background To investigate the changing pattern of adenocarcinoma of the esophagogastric junction subtypes and its time trend relationship with that of reflux esophagitis over 10 years at a tertiary medical center in China.
Zhi-wei Xia, Michael McNutt, Chang-qing Yang, Xue-song Yang, Kun Wang, Rong-li Cui, Li-ping Duan, Zhu Jin   +7 more
core   +1 more source

Serum insulin-like growth factor binding protein 3 as a promising diagnostic and prognostic biomarker in esophagogastric junction adenocarcinoma

Discover Oncology, 2022
Background Esophagogastric junction adenocarcinoma (EJA) lacks serum biomarkers to assist in diagnosis and prognosis. Here, we aimed to evaluate the diagnostic and prognostic value of serum insulin-like growth factor binding protein 3 (IGFBP3) in EJA ...
Tian-Yan Ding, Yu-Hui Peng, Chao-Qun Hong, Bin-Liang Huang, Can-Tong Liu, Yun Luo, Ling-Yu Chu, Biao Zhang, Xin-Hao Li, Qi-Qi Qu, Yi-Wei Xu, Fang-Cai Wu   +11 more
doaj   +1 more source

Extent of Lymph Node Dissection for cStage I Siewert Type I/II Cancers Based on Lymph Node Metastasis Risk Stratification

Annals of Gastroenterological Surgery, Volume 10, Issue 5, Page 1478-1485, September 2026.
ABSTRACT Aim The optimal surgical strategy and extent of lymph node (LN) dissection for clinical Stage I (cStage I) adenocarcinoma of the esophagogastric junction (AEG) remain controversial. This study aimed to evaluate surgical outcomes and clarify the prevalence and distribution of LN metastasis according to tumor characteristics in cStage I Siewert ...
Masayoshi Terayama, Akihiko Okamura, Tomoyuki Irino, Naoki Takahashi, Jun Kanamori, Yu Imamura, Masaru Hayami, Motonari Ri, Souya Nunobe, Masayuki Watanabe   +9 more
wiley   +1 more source